Melanie S. Bailey Published in Cincinnati Bar Association Report
Melaine S. Bailey authored an article published in the CBA Report regarding the ability of consumers to hold drug manufacturers liable for failure to warn of adverse reactions to prescription medications. In the article, Brand Name Drug or Generic Drug: Generic may foil your client’s failure to warn case, Jan/Feb 2019 CBA Report, Ms. Bailey explains how decisions from the Supreme Court differentiates the responsibilities of manufacturers of brand name drugs versus generic drugs and how that may hamper your ability to hold generic drug manufacturers responsible for failing to warn about potential side effects of their drugs.
To read the article, click here.
Ms. Melanie Bailey is a shareholder at Burg Simpson in Cincinnati, OH. Prior to joining Burg Simpson Eldredge Hersh & Jardine, P.C., Ms. Bailey worked for law firms in Kentucky and Ohio, practicing in the areas of complex civil litigation and class action litigation. In 2006, she was court appointed Class Counsel in a class action employment case on behalf of Wal-Mart employees in the state of Kentucky. Melanie is a member of the firm’s Cincinnati office and practices in the areas of complex civil litigation, pharmaceutical and general products liability, multi-district litigation, personal injury, wrongful death, and class action litigation. During her tenure at Burg Simpson, Melanie has devoted time to working on pharmaceutical cases, such as Ortho Evra, contaminated Heparin, Yasmin/Yaz, and Depakote. She has also litigated several product liability cases for defective medical devices, such as hip replacements and knee replacements.